BLX 7006
Alternative Names: MLX-7000Latest Information Update: 18 Jan 2024
At a glance
- Originator Biolexis Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus